Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Completed · Phase 1 · Has a placebo group

Conditions studied: Diabetes, Diabetes Mellitus, Type 2

In brief

This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in subjects with type 2 diabetes.

Key facts

Study ID

NCT01511185

Run by

Novo Nordisk A/S

People needed

20

Starts

2001-02-01

Expected to finish

2001-10-01

Last updated by the study team

2017-01-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on OAD monotherapy for at least 3 months
• Body Mass Index (BMI): 24-35 kg/m\^2 inclusive

You may not qualify if…

• SUBJECTS WITH TYPE 2 DIABETES
• Receipt of any investigational drug within three months prior to this trial
• Recurrent severe hypoglycemia as judged by the investigator
• Cardiac disease
• Use of any drug (except an OAD (oral anti-diabetic drug)) that in the investigator's opinion could interfere with the blood glucose level
• Haemoglobin maximum 10 g/L
• HbA1c above 12%
• Loss of more than 400 mL blood during the 3 months prior to trial start
• HEALTHY SUBJECTS
• Receipt of any investigational drug within 3 months prior to this trial
• Clinically relevant cardiac disease or any clinically significant abnormal ECG (electrocardiogram)
• Use of any drug that in the investigator's opinion could interfere with the blood glucose level
• Haemoglobin max. 10 g/L
• HbA1c at least 6%

Where it is running

• Novo Nordisk Investigational Site — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.